No evidence to support the price variation in heart valves used by the NHS
Draft guidance issued today (9 August) states that the variation in price the NHS is paying for valves used in keyhole heart procedures is not supported by reliable evidence.
Draft guidance issued today (9 August) states that the variation in price the NHS is paying for valves used in keyhole heart procedures is not supported by reliable evidence.
Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.
Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.
Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.
Giving a new clot-busting drug to people who have had a stroke could help save the NHS millions of pounds.
Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.
Page 2 of 29